NewAmsterdam Pharma Company N.V. Warrant
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. Th… Read more
NewAmsterdam Pharma Company N.V. Warrant (NAMSW) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.045x
Based on the latest financial reports, NewAmsterdam Pharma Company N.V. Warrant (NAMSW) has a cash flow conversion efficiency ratio of -0.045x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.77 Million) by net assets ($728.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NewAmsterdam Pharma Company N.V. Warrant - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how NewAmsterdam Pharma Company N.V. Warrant's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
NewAmsterdam Pharma Company N.V. Warrant Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NewAmsterdam Pharma Company N.V. Warrant ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Richelieu Hardware Ltd
PINK:RHUHF
|
0.071x |
|
Mr D.I.Y. Group (M) Berhad
OTCGREY:MDIYF
|
0.054x |
|
Invisio AB
LSE:0R86
|
0.103x |
|
S-1 Corp
KO:012750
|
0.070x |
|
SPG Co. Ltd
KQ:058610
|
0.063x |
|
Hyundai Doosan Infracore Co Ltd
KO:042670
|
0.072x |
|
Now Inc
NYSE:DNOW
|
0.036x |
|
Xiangcai Co Ltd
SHG:600095
|
-0.134x |
Annual Cash Flow Conversion Efficiency for NewAmsterdam Pharma Company N.V. Warrant (2020–2024)
The table below shows the annual cash flow conversion efficiency of NewAmsterdam Pharma Company N.V. Warrant from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $757.50 Million | $-158.56 Million | -0.209x | +57.25% |
| 2023-12-31 | $288.39 Million | $-141.22 Million | -0.490x | -2074.60% |
| 2022-12-31 | $430.07 Million | $10.66 Million | 0.025x | +104.76% |
| 2021-12-31 | $56.63 Million | $-29.51 Million | -0.521x | -804.70% |
| 2020-12-31 | $127.46 Million | $-7.34 Million | -0.058x | -- |